An observational, multinational, multi-center, prospective, open-label study to asses effectiveness, safety and tolerability of treatment with vildagliptin or vildagliptin plus metformin (SPC) in type 2 diabetes mellitus patients in a real-world setting - GUARD

Trial Profile

An observational, multinational, multi-center, prospective, open-label study to asses effectiveness, safety and tolerability of treatment with vildagliptin or vildagliptin plus metformin (SPC) in type 2 diabetes mellitus patients in a real-world setting - GUARD

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Vildagliptin/metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GUARD
  • Sponsors Novartis Healthcare
  • Most Recent Events

    • 01 May 2017 Results (n=2786) assessing the effectiveness, safety, and tolerability of vildagliptin treatment with or without metformin in the patient subset from Egypt, published in the Current Medical Research and Opinion.
    • 30 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top